Which are the factors that determine the course of a Covid-19 infection? Whether patients develop symptoms, whether they fall seriously ill, whether they need to be treated in a hospital?
A decisive factor seems to be the age of the patient...
Is MetrioPharm developing a compound for the treatment of COVID-19?
Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...
Eva Brysch
Head of Investor Relations & Corporate Communications
invest@metriopharm.com
Ralf Haubert
Marketing Manager
blog@metriopharm.com
© MetrioPharm AG 2019
